Tuesday, November 11, 2025 11:40:28 AM
MNOV.................................https://stockcharts.com/sc3/ui/?s=MNOV&p=W&b=5&g=0&id=p86431144783
Recent MNOV News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 08:32:35 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:26:29 PM
- New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation • GlobeNewswire Inc. • 04/27/2026 11:00:00 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/20/2026 09:03:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:57:21 PM
- MediciNova to Participate at the 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 11:25:19 AM
- MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients • GlobeNewswire Inc. • 01/29/2026 11:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 10:04:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 10:03:52 PM
- 2026 New Year’s Greetings from the CEO • GlobeNewswire Inc. • 01/06/2026 02:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/30/2025 12:55:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/30/2025 12:53:12 PM
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy • GlobeNewswire Inc. • 12/18/2025 11:00:00 AM
- MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND • GlobeNewswire Inc. • 12/08/2025 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/05/2025 09:23:58 PM
- Message from the CEO to MediciNova Shareholders • GlobeNewswire Inc. • 12/01/2025 11:00:00 PM
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor • GlobeNewswire Inc. • 11/18/2025 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:35:02 PM
- MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards • GlobeNewswire Inc. • 11/06/2025 11:00:00 PM
- MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) • GlobeNewswire Inc. • 11/04/2025 12:00:00 PM
- MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication • GlobeNewswire Inc. • 10/30/2025 11:00:00 PM
- MediciNova to Present at the LD Micro Main Event XIX Investor Conference • GlobeNewswire Inc. • 10/06/2025 12:00:00 PM
